The folate receptor: What does it promise in tissue-targeted therapeutics?

Cancer and Metastasis Reviews

Volumn 26, Issue 1, 2007, Pages 141-152

  Salazar, Marcela D'Alincourt ^a   Ratnam, Manohar ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Antifolate; Folate conjugate; Folate receptor; Immunotherapy; Tumor imaging; Tumor target

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOXORUBICIN; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; FOLATE RECEPTOR BETA; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLIC ACID DERIVATIVE; FULVESTRANT; GELONIN; HISTONE DEACETYLASE INHIBITOR; ISOPROTEIN; LIPOSOME; LYMPHOCYTE ANTIBODY; NANOPARTICLE; PACLITAXEL; PENTETATE INDIUM IN 111; PENTETATE TECHNETIUM TC 99M; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; RETINOIC ACID; T LYMPHOCYTE RECEPTOR ANTIBODY; TAMOXIFEN; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ASCITES TUMOR; BONE MARROW; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL INFILTRATION; CELL STRAIN 3T3; CHOROID PLEXUS TUMOR; DIAGNOSTIC IMAGING; DNA POLYMORPHISM; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; FLOW CYTOMETRY; FOLATE RECEPTOR GAMMA GENE; GENE; GENE MUTATION; GENOME; HUMAN; IMMUNE RESPONSE; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LIPID RAFT; LUNG CANCER; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SCID MOUSE; T LYMPHOCYTE; TESTIS CANCER; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; UTERUS CANCER; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; FOLIC ACID; HUMANS; LEUKEMIA, MYELOID; PROTEIN ISOFORMS; RECEPTORS, CELL SURFACE;

EID: 33947362046     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9048-0     Document Type: Review

References (125)

1. Stover, P. J. (2004). Physiology of folate and vitamin B12 in health and disease. Nutrition Reviews, 62, S3-S12, discussion S13.
2. Blom, H. J., Shaw, G. M., den Heijer, M., & Finnell, R. H. (2006). Neural tube defects and folate: Case far from closed. Nature Reviews. Neuroscience, 7, 724-731.
3. Smulders, Y. M., & Stehouwer, C. D. (2005). Folate metabolism and cardiovascular disease. Seminars in Vascular Medicine, 5, 87-97.
4. Moat, S. J., Lang, D., McDowell, I. F., Clarke, Z. L., Madhavan, A. K., Lewis, M. J., et al. (2004). Folate, homocysteine, endothelial function and cardiovascular disease. Journal of Nutritional Biochemistry, 15, 64-79.
5. Matherly, L. H., & Goldman, D. I. (2003). Membrane transport of folates. Vitamins and Hormones, 66, 403-456.
6. Qiu, A., Jansen, M., Sakaris, A., Min, S. H., Chattopadhyay, S., Tsai, E., et al. (2006). Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell, 127, 917-928.
7. Antony, A. C. (1992). The biological chemistry of folate receptors. Blood, 79, 2807-2820.
8. Kamen, B. A., & Smith, A. K. (2004). A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Advanced Drug Delivery Reviews, 56, 1085-1097.
9. Piedrahita, J. A., Oetama, B., Bennett, G. D., van Waes, J., Kamen, B. A., Richardson, J., et al. (1999). Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nature Genetics, 23, 228-232.
10. Reddy, J. A., Allagadda, V. M., & Leamon, C. P. (2005). Targeting therapeutic and imaging agents to folate receptor positive tumors. Current Pharmaceutical Biotechnology, 6, 131-150.
11. Elnakat, H., & Ratnam, M. (2004). Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Advanced Drug Delivery Reviews, 56, 1067-1084.
12. Shen, F., Ross, J. F., Wang, X., & Ratnam, M. (1994). Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry, 33, 1209-1215.
13. Spiegelstein, O., Eudy, J. D., & Finnell, R. H. (2000). Identification of two putative novel folate receptor genes in humans and mouse. Gene, 258, 117-125.
14. Ragoussis, J., Senger, G., Trowsdale, J., & Campbell, I. G. (1992). Genomic organization of the human folate receptor genes on chromosome 11q13. Genomics, 14, 423-430.
15. Shen, F., Wu, M., Ross, J. F., Miller, D., & Ratnam, M. (1995). Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: Protein characterization and cell type specificity. Biochemistry, 34, 5660-5665.
16. Lacey, S. W., Sanders, J. M., Rothberg, K. G., Anderson, R. G., & Kamen, B. A. (1989). Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. Journal of Clinical Investigation, 84, 715-720.
17. Yan, W., & Ratnam, M. (1995). Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal. Biochemistry, 34, 14594-14600.
18. Luhrs, C. A., & Slomiany, B. L. (1989). A human membrane-associated folate binding protein is anchored by a glycosylphosphatidylinositol tail. Journal of Biological Chemistry, 264, 21446-21449.
19. Antony, A. C., Verma, R. S., Unune, A. R., & LaRosa, J. A. (1989). Identification of a Mg2+-dependent protease in human placenta which cleaves hydrophobic folate-binding proteins to hydrophilic forms. Journal of Biological Chemistry, 264, 1911-1914.
20. Elwood, P. C., Deutsch, J. C., & Kolhouse, J. F. (1991). The conversion of the human membrane-associated folate binding protein (folate receptor) to the soluble folate binding protein by a membrane-associated metalloprotease. Journal of Biological Chemistry, 266, 2346-2353.
21. Yang, X. Y., Mackins, J. Y., Li, Q. J., & Antony, A. C. (1996). Isolation and characterization of a folate receptor-directed metalloprotease from human placenta. Journal of Biological Chemistry, 271, 11493-11499.
22. Wang, J., Shen, F., Yan, W., Wu, M., & Ratnam, M. (1997). Proteolysis of the carboxyl-terminal GPI signal independent of GPI modification as a mechanism for selective protein secretion. Biochemistry, 36, 14583-14592.
23. Ratnam, M., Marquardt, H., Duhring, J. L., & Freisheim, J. H. (1989). Homologous membrane folate binding proteins in human placenta: Cloning and sequence of a cDNA. Biochemistry, 28, 8249-8254.
24. Shen, F., Wang, H., Zheng, X., & Ratnam, M. (1997). Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites. Biochemical Journal, 327(Pt 3), 759-764.
25. Zheng, X., Kelley, K., Elnakat, H., Yan, W., Dorn, T., & Ratnam, M. (2003). mRNA instability in the nucleus due to a novel open reading frame element is a major determinant of the narrow tissue specificity of folate receptor alpha. Molecular and Cellular Biology, 23, 2202-2212.
26. Wang, X., Shen, F., Freisheim, J. H., Gentry, L. E., & Ratnam, M. (1992). Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochemical Pharmacology, 44, 1898-1901.
27. Maziarz, K. M., Monaco, H. L., Shen, F., & Ratnam, M. (1999). Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. Journal of Biological Chemistry, 274, 11086-11091.
28. Monaco, H. L. (1997). Crystal structure of chicken riboflavin-binding protein. EMBO Journal, 16, 1475-1483.
29. Edidin, M. (2003). The state of lipid rafts: From model membranes to cells. Annual Review of Biophysics and Biomolecular Structure, 32, 257-283.
30. Vereb, G., Szollosi, J., Matko, J., Nagy, P., Farkas, T., Vigh, L., et al. (2003). Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model. Proceedings of the National Academy of Sciences of the United States of America, 100, 8053-8058.
31. Sabharanjak, S., Sharma, P., Parton, R. G., & Mayor, S. (2002). GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Developmental Cell, 2, 411-423.
32. Nichols, B. J., Kenworthy, A. K., Polishchuk, R. S., Lodge, R., Roberts, T. H., Hirschberg, K., et al. (2001). Rapid cycling of lipid raft markers between the cell surface and Golgi complex. Journal of Cell Biology, 153, 529-541.
33. Wu, M., Fan, J., Gunning, W., & Ratnam, M. (1997). Clustering of GPI-anchored folate receptor independent of both crosslinking and association with caveolin. Journal of Membrane Biology, 159, 137-147.
34. Friedrichson, T., & Kurzchalia, T. V. (1998). Microdomains of GPI-anchored proteins in living cells revealed by crosslinking. Nature, 394, 802-805.
35. Varma, R., & Mayor, S. (1998). GPI-anchored proteins are organized in submicron domains at the cell surface. Nature, 394, 798-801.
36. Birn, H., Selhub, J., & Christensen, E. I. (1993). Internalization and intracellular transport of folate-binding protein in rat kidney proximal tubule. American Journal of Physiology, 264, C302-310.
37. Hjelle, J. T., Christensen, E. I., Carone, F. A., & Selhub, J. (1991). Cell fractionation and electron microscope studies of kidney folate-binding protein. American Journal of Physiology, 260, C338-346.
38. Mayor, S., Sabharanjak, S., & Maxfield, F. R. (1998). Cholesterol-dependent retention of GPI-anchored proteins in endosomes. EMBO Journal, 17, 4626-4638.
39. Kamen, B. A., Wang, M. T., Streckfuss, A. J., Peryea, X., & Anderson, R. G. (1988). Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. Journal of Biological Chemistry, 263, 13602-13609.
40. Kamen, B. A., Johnson, C. A., Wang, M. T., & Anderson, R. G. (1989). Regulation of the cytoplasmic accumulation of 5-methyltetrahydrofolate in MA104 cells is independent of folate receptor regulation. Journal of Clinical Investigation, 84, 1379-1386.
41. Rothberg, K. G., Ying, Y. S., Kolhouse, J. F., Kamen, B. A., & Anderson, R. G. (1990). The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. Journal of Cell Biology, 110, 637-649.
42. Ritter, T. E., Fajardo, O., Matsue, H., Anderson, R. G., & Lacey, S. W. (1995). Folate receptors targeted to clathrin-coated pits cannot regulate vitamin uptake. Proceedings of the National Academy of Sciences of the United States of America, 92, 3824-3828.
43. Chang, W. J., Rothberg, K. G., Kamen, B. A., & Anderson, R. G. (1992). Lowering the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate. Journal of Cell Biology, 118, 63-69.
44. Leamon, C. P., & Low, P. S. (1991). Delivery of macromolecules into living cells: A method that exploits folate receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 88, 5572-5576.
45. Leamon, C. P., & Low, P. S. (1993). Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochemical Journal, 291(Pt 3), 855-860.
46. Turek, J. J., Leamon, C. P., & Low, P. S. (1993). Endocytosis of folate-protein conjugates: Ultrastructural localization in KB cells. Journal of Cell Science, 106(Pt 1), 423-430.
47. Rijnboutt, S., Jansen, G., Posthuma, G., Hynes, J. B., Schornagel, J. H., & Strous, G. J. (1996). Endocytosis of GPI-linked membrane folate receptor-alpha. Journal of Cell Biology, 132, 35-47.
48. Leamon, C. P., & Low, P. S. (2001). Folate-mediated targeting: From diagnostics to drug and gene delivery. Drug Discovery Today, 6, 44-51.
49. Miotti, S., Canevari, S., Menard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., et al. (1987). Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. International Journal of Cancer, 39, 297-303.
50. Weitman, S. D., Weinberg, A. G., Coney, L. R., Zurawski, V. R., Jennings, D. S., & Kamen, B. A. (1992). Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis. Cancer Research, 52, 6708-6711.
51. Chancy, C. D., Kekuda, R., Huang, W., Prasad, P. D., Kuhnel, J. M., Sirotnak, F. M., et al. (2000). Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. Journal of Biological Chemistry, 275, 20676-20684.
52. Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M., & Boiocchi, M. (1997). Overexpression of folate binding protein in ovarian cancers. International Journal of Cancer, 74, 193-198.
53. Ross, J. F., Chaudhuri, P. K., & Ratnam, M. (1994). Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 73, 2432-2443.
54. Bueno, R., Appasani, K., Mercer, H., Lester, S., & Sugarbaker, D. (2001). The alpha folate receptor is highly activated in malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery, 121, 225-233.
55. Evans, C. O., Young, A. N., Brown, M. R., Brat, D. J., Parks, J. S., Neish, A. S., et al. (2001). Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. Journal of Clinical Endocrinology and Metabolism, 86, 3097-3107.
56. Weitman, S. D., Frazier, K. M., & Kamen, B. A. (1994). The folate receptor in central nervous system malignancies of childhood. Journal of Neuro-oncology, 21, 107-112.
57. Wu, M., Gunning, W., & Ratnam, M. (1999). Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiology, Biomarkers & Prevention, 8, 775-782.
58. Buist, M. R.,Molthoff, C. F., Kenemans, P., & Meijer, C. J. (1995). Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. Journal of Clinical Pathology, 48, 631-636.
59. Figini, M., Ferri, R., Mezzanzanica, D., Bagnoli, M., Luison, E., Miotti, S., et al. (2003). Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Therapy, 10, 1018-1025.
60. Wang, H., Zheng, X., Behm, F. G., & Ratnam, M. (2000). Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood, 96, 3529-3536.
61. Ross, J. F., Wang, H., Behm, F. G., Mathew, P., Wu, M., Booth, R., et al. (1999). Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer, 85, 348-357.
62. Reddy, J. A., Haneline, L. S., Srour, E. F., Antony, A. C., Clapp, D. W., & Low, P. S. (1999). Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood, 93, 3940-3948.
63. Nakashima-Matsushita, N., Homma, T., Yu, S., Matsuda, T., Sunahara, N., Nakamura, T., et al. (1999). Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis and Rheumatism, 42, 1609-1616.
64. Sun, X. L., Murphy, B. R., Li, Q. J., Gullapalli, S., Mackins, J., Jayaram, H. N., et al. (1995). Transduction of folate receptor cDNA into cervical carcinoma cells using recombinant adeno-associated virions delays cell proliferation in vitro and in vivo. Journal of Clinical Investigation, 96, 1535-1547.
65. Pan, X. Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., & Lee, R. J. (2002). Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood, 100, 594-602.
66. Westerhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., et al. (1995). Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular-structure and biological activity. Molecular Pharmacology, 48, 459-471.
67. Theti, D. S., Bavetsias, V., Skelton, L. A., Titley, J., Gibbs, D., Jansen, G., et al. (2003). Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Research, 63, 3612-3618.
68. Bavetsias, V., Marriott, J. H., Melin, C., Kimbell, R., Matusiak, Z. S., Boyle, F. T., et al. (2000). Design and synthesis of Cyclopenta[g]quinazoline- based antifolates as inhibitors of thymidylate synthase and potential antitumor agents. Journal of Medicinal Chemistry, 43, 1910-1926.
69. Gibbs, D. D., Theti, D. S., Wood, N., Green, M., Raynaud, F., Valenti, M., et al. (2005). BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Research, 65, 11721-11728.
70. Jackman, A. L., Theti, D. S., & Gibbs, D. D. (2004). Antifolates targeted specifically to the folate receptor. Advanced Drug Delivery Reviews, 56, 1111-1125.
71. Lee, J. W., Lu, J. Y., Low, P. S., & Fuchs, P. L. (2002). Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics. Bioorganic & Medicinal Chemistry, 10, 2397-2414.
72. Aronov, O., Horowitz, A. T., Gabizon, A., & Gibson, D. (2003). Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjugate Chemistry, 14, 563-574.
73. Atkinson, S. F., Bettinger, T., Seymour, L. W., Behr, J. P., & Ward, C. M. (2001). Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. Journal of Biological Chemistry, 276, 27930-27935.
74. Mathias, C. J., Hubers, D., Low, P. S., & Green, M. A. (2000). Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor- targeted radiopharmaceutical. Bioconjugate Chemistry, 11, 253-257.
75. Mathias, C. J., Wang, S., Waters, D. J., Turek, J. J., Low, P. S., & Green, M. A. (1998). Indium-111-DTPA-folate as a potential folate-receptor- targeted radiopharmaceutical. Journal of Nuclear Medicine, 39, 1579-1585.
76. Wang, S., Luo, J., Lantrip, D. A., Waters, D. J., Mathias, C. J., Green, M. A., et al. (1997). Design and synthesis of [111In] DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chemistry, 8, 673-679.
77. Leamon, C. P., Parker, M. A., Vlahov, I. R., Xu, L. C., Reddy, J. A., Vetzel, M., et al. (2002). Synthesis and biological evaluation of EC20: A new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjugate Chemistry, 13, 1200-1210.
78. Reddy, J. A., Xu, L. C., Parker, N., Vetzel, M., & Leamon, C. P. (2004). Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. Journal of Nuclear Medicine, 45, 857-866.
79. Guo, W., Hinkle, G. H., & Lee, R. J. (1999). 99mTc-HYNICfolate: A novel receptor-based targeted radiopharmaceutical for tumor imaging. Journal of Nuclear Medicine, 40, 1563-1569.
80. Wang, S., Lee, R. J., Mathias, C. J., Green, M. A., & Low, P. S. (1996). Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine- folate, a potential radiopharmaceutical for tumor imaging. Bioconjugate Chemistry, 7, 56-62.
81. Mathias, C. J., Wang, S., Low, P. S., Waters, D. J., & Green, M. A. (1999). Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nuclear Medicine and Biology, 26, 23-25.
82. Trump, D. P., Mathias, C. J., Yang, Z., Low, P. S., Marmion, M., & Green, M. A. (2002). Synthesis and evaluation of 99mTc(CO) (3)-DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nuclear Medicine and Biology, 29, 569-573.
83. Ke, C. Y., Mathias, C. J., & Green, M. A. (2004). Folatereceptor-targeted radionuclide imaging agents. Advanced Drug Delivery Reviews, 56, 1143-1160.
84. Siegel, B. A., Dehdashti, F., Mutch, D. G., Podoloff, D. A., Wendt, R., Sutton, G. P., et al. (2003). Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: Initial clinical results. Journal of Nuclear Medicine, 44, 700-707.
85. Lee, R. J., & Low, P. S. (1994). Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. Journal of Biological Chemistry, 269, 3198-3204.
86. Lee, R. J., & Low, P. S. (1995). Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochimica et Biophysica Acta, 1233, 134-144.
87. Pan, X. Q., Wang, H., & Lee, R. J. (2003). Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharmaceutical Research, 20, 417-422.
88. Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., & Gabizon, A. (2000). Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clinical Cancer Research, 6, 1949-1957.
89. Wang, S., Lee, R. J., Cauchon, G., Gorenstein, D. G., & Low, P. S. (1995). Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proceedings of the National Academy of Sciences of the United States of America, 92, 3318-3322.
90. Lee, R. J., & Huang, L. (1996). Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. Journal of Biological Chemistry, 271, 8481-8487.
91. Gosselin, M. A., Guo, W., & Lee, R. J. (2002). Incorporation of reversibly cross-linked polyplexes into LPDII vectors for gene delivery. Bioconjugate Chemistry, 13, 1044-1053.
92. Gabizon, A., Shmeeda, H., Horowitz, A. T., & Zalipsky, S. (2004). Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Advanced Drug Delivery Reviews, 56, 1177-1192.
93. Leamon, C. P., Cooper, S. R., & Hardee, G. E. (2003). Folateliposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: Evaluation in vitro and in vivo. Bioconjugate Chemistry, 14, 738-747.
94. Reddy, J. A., & Low, P. S. (2000). Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. Journal of Controlled Release, 64, 27-37.
95. Choi, H., Choi, S. R., Zhou, R., Kung, H. F., & Chen, I. W. (2004). Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Academic Radiology, 11, 996-1004.
96. Sonvico, F., Mornet, S., Vasseur, S., Dubernet, C., Jaillard, D., Degrouard, J., et al. (2005). Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chemistry, 16, 1181-1188.
97. Rossin, R., Pan, D., Qi, K., Turner, J. L., Sun, X., Wooley, K. L., et al. (2005). 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: Synthesis, radiolabeling, and biologic evaluation. Journal of Nuclear Medicine, 46, 1210-1218.
98. Santra, S., Liesenfeld, B., Dutta, D., Chatel, D., Batich, C. D., Tan, W., et al. (2005). Folate conjugated fluorescent silica nanoparticles for labeling neoplastic cells. Journal of Nanoscience and Nanotechnology, 5, 899-904.
99. Bharali, D. J., Lucey, D. W., Jayakumar, H., Pudavar, H. E., & Prasad, P. N. (2005). Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. Journal of the American Chemical Society, 127, 11364-11371.
100. Kam, N. W., O'Connell, M., Wisdom, J. A., & Dai, H. (2005). Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proceedings of the National Academy of Sciences of the United States of America, 102, 11600-11605.
101. Zheng, G., Chen, J., Li, H., & Glickson, J. D. (2005). Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proceedings of the National Academy of Sciences of the United States of America, 102, 17757-17762.
102. Coney, L. R., Tomassetti, A., Carayannopoulos, L., Frasca, V., Kamen, B. A., Colnaghi, M. I., et al. (1991). Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Research, 51, 6125-6132.
103. Kranz, D. M., Patrick, T. A., Brigle, K. E., Spinella, M. J., & Roy, E. J. (1995). Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proceedings of the National Academy of Sciences of the United States of America, 92, 9057-9061.
104. Roy, E. J., Cho, B. K., Rund, L. A., Patrick, T. A., & Kranz, D. M. (1998). Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate. International Journal of Cancer, 76, 761-766.
105. Lu, Y., & Low, P. S. (2002). Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunology and Immunotherapy, 51, 153-162.
106. Ratnam, M., Hao, H., Zheng, X., Wang, H., Qi, H., Lee, R., et al. (2003). Receptor induction and targeted drug delivery: A new antileukaemia strategy Expert Opinion on Biological Therapy, 3, 563-574.
107. Frankel, A. E., Sievers, E. L., & Scheinberg, D. A. (2000). Cell surface receptor-targeted therapy of acute myeloid leukemia: A review. Cancer Biotherapy & Radiopharmaceuticals, 15, 459-476.
108. Naito, K., Takeshita, A., Shigeno, K., Nakamura, S., Fujisawa, S., Shinjo, K., et al. (2000). Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia, 14, 1436-1443.
109. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
110. Zhong, R. K., van de Winkel, J. G., Thepen, T., Schultz, L. D., & Ball, E. D. (2001). Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. Journal of Hematotherapy and Stem Cell Research, 10, 95-105.
111. Flavell, D. J., Boehm, D. A., Noss, A., Warnes, S. L., & Flavell, S. U. (2001). Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. British Journal of Cancer, 84, 571-578.
112. Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., et al. (2000). Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Journal of Clinical Oncology, 18, 1622-1636.
113. Pagliaro, L. C., Liu, B., Munker, R., Andreeff, M., Freireich, E. J., Scheinberg, D. A., et al. (1998). Humanized M195 monoclonal antibody conjugated to recombinant gelonin: An anti-CD33 immunotoxin with antileukemic activity. Clinical Cancer Research, 4, 1971-1976.
114. Kreitman, R. J., & Pastan, I. (1997). Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood, 90, 252-259.
115. Wang, Y., Eksborg, S., Lewensohn, R., Lindberg, A., & Liliemark, E. (1999). In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells. Anti-cancer Drugs, 10, 921-928.
116. Ma, D. D., & Wei, A. Q. (1996). Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leukemia Research, 20, 925-930.
117. Lopes de Menezes, D. E., Pilarski, L. M., Belch, A. R., & Allen, T. M. (2000). Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochimica et Biophysica Acta, 1466, 205-220.
118. Suzuki, S., Inoue, K., Hongoh, A., Hashimoto, Y., & Yamazoe, Y. (1997). Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. British Journal of Cancer, 76, 83-89.
119. Ohta, S., Igarashi, S., Honda, A., Sato, S., & Hanai, N. (1993). Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies. Anticancer Research, 13, 331-336.
120. Kelley, K. M., Rowan, B. G., & Ratnam, M. (2003). Modulation of the folate receptor alpha gene by the estrogen receptor: Mechanism and implications in tumor targeting. Cancer Research, 63, 2820-2828.
121. Tran, T., Shatnawi, A., Zheng, X., Kelley, K. M., & Ratnam, M. (2005). Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: A promising means to improved tumor detection and targeting. Cancer Research, 65, 4431-4441.
122. Hao, H., Qi, H., & Ratnam, M. (2003). Modulation of the folate receptor type beta gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites. Blood, 101, 4551-4560.
123. Qi, H., & Ratnam, M. (2006). Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Research, 66, 5875-5882.
124. Christensen, E. I., Birn, H., Verroust, P., & Moestrup, S. K. (1998) Membrane receptors for endocytosis in the renal proximal tubule. Int. Rev. Cytol., 180, 237-284.
125. Lee, R. J., & Low, P. S. (1994) Delivery of liposomes into cultured KB cells via Folate receptor-mediated endocytosis. J. Biol. Chem. 269, 3198-3204.